Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Spotlight on eletriptan in migraine.

Paul L McCormack1, Gillian M Keating

  • 1Wolters Kluwer Health, Adis, Auckland, New Zealand. demail@adis.co.nz

CNS Drugs
|October 19, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Afatinib in advanced NSCLC: a profile of its use.

Drugs & therapy perspectives : for rational drug selection and use·2019
Same author

Afatinib in advanced NSCLC: a profile of its use.

Drugs & therapy perspectives : for rational drug selection and use·2018
Same author

Ticagrelor: A Review in Long Term Secondary Prevention of Cardiovascular Events.

Drugs·2017
Same author

Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome.

Drugs·2017
Same author

Sorafenib: A Review in Hepatocellular Carcinoma.

Targeted oncology·2017
Same author

Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex<sup>®</sup>): A Review in Multiple Sclerosis-Related Spasticity.

Drugs·2017
Same journal

Impact of Omaveloxolone on Serum Lipids in Patients with Friedreich Ataxia: A 1-Year Real-World Analysis.

CNS drugs·2026
Same journal

Emerging Pharmacological Strategies for Trigeminal Neuralgia.

CNS drugs·2026
Same journal

Psychiatric Symptoms Associated with Corticosteroid Use: A Systematic Review and Meta-analysis.

CNS drugs·2026
Same journal

Anti-CD20 Therapies in Pediatric Acquired Demyelinating Syndromes: Evidence Across MS, AQP4-IgG-Positive NMOSD and MOGAD.

CNS drugs·2026
Same journal

Isoform-Specific NaV Modulation in Painful Chemotherapy-Induced Neuropathy: Promise, Limitations, and a Clinical Agenda.

CNS drugs·2026
Same journal

Correction: Seletracetam Revisited: A Missed Opportunity for Effective Epilepsy Therapy.

CNS drugs·2026
See all related articles

Eletriptan effectively treats moderate to severe migraine attacks in adults, showing rapid action and superiority over placebo. It is well-tolerated and a valuable first-line option within the triptan class.

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Migraine is a common neurological disorder.
  • Acute treatment options are crucial for managing migraine attacks.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of eletriptan for acute migraine treatment.
  • To compare eletriptan with placebo and other triptans.

Main Methods:

  • Oral administration of eletriptan (20, 40, or 80 mg) or comparator drugs.
  • Assessment of efficacy endpoints at various time points post-administration.

Main Results:

  • Eletriptan demonstrated rapid onset of action, superior to placebo within 30 minutes.
  • Higher doses of eletriptan showed greater efficacy compared to sumatriptan, naratriptan, and zolmitriptan.

Related Experiment Videos

  • Eletriptan was well-tolerated and improved quality of life.

    • Conclusions:

    • Eletriptan is an effective and well-tolerated treatment for acute migraine.
    • It offers advantages over placebo and several other triptans.
    • Eletriptan is a recommended first-line option for migraine management.